Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing, licensing, and commercializing therapeutics for human diseases, particularly in central nervous system (CNS) disorders [2] - The company has a pipeline that includes product candidates for fibromyalgia, acute stress reaction, cocaine intoxication, organ transplant rejection, autoimmunity, and cancer [2] Recent Developments - Tonix has been awarded an Other Transaction Agreement (OTA) with the Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop broad-spectrum antiviral agents [13][18] - The funding aims to enhance the medical readiness of military personnel in biological threat environments and supports the company's antiviral discovery program [9][18] Product Pipeline - Tonix's priority is to submit a New Drug Application (NDA) for Tonmya (TNX-102 SL) in the second half of 2024, which has completed two statistically significant Phase 3 studies for fibromyalgia management [2][7] - The company is also developing TNX-1300 for cocaine intoxication and TNX-1500, a monoclonal antibody for preventing organ transplant rejection and treating autoimmune diseases [2] Research and Development Facilities - Tonix utilizes advanced research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility located in Frederick, Maryland [1] Strategic Focus - The company is focusing on optimizing its TNX-4200 program, which aims to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families [5][18] - Tonix's approach includes leveraging previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention against biothreat agents [18]

Tonix Pharmaceuticals doesn't have the finer details of this offering ready just yet. That means we don't know how many shares it includes, what they will be priced at or how much it expects in gross proceeds. To be more specific, Tonix Pharmaceuticals wants to use the money to prepare a new drug application for its Tonmya product candidate to treat fibromyalgia. It could also use the funds to pay down its debts. Investors will note that Tonix Pharmaceuticals announced this proposed public offering right af ...

CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and sale of approximately 7,060,918 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.57 per share (or $0.569 per pre-funded warrant in lieu thereof). The closing of the public offering is expected to take place ...

CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and sale of approximately 7,060,918 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.57 per share (or $0.569 per pre-funded warrant in lieu thereof). The closing of the public offering is expected to take place ...

CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On June 26, 2024, Tonix received a letter from The Nasdaq Stock Market LLC stating that because Tonix's shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business ...

Tonix's live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with intratracheal monkeypox Clade II mpox is now endemic in the U.S. with >30,000 cases reported since May 20221 and Clade I mpox is endemic in the Democratic Republic of the Congo2 Tonix's vaccine platform has been selected by NIH's Project NextGen for clinical testing CHATHAM, N.J., June 25, 2024 (GLOBE NE ...

"People suffering with fibromyalgia tend to struggle with daily activities, have impaired quality of life and are frequently disabled", said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "We believe the activity of Tonmya on pain, sleep quality, fatigue cognitive dysfunction, and depression are indicative of the broad-spectrum activity of Tonmya, suggesting Tonmya treats fibromyalgia at a syndromal level. We are excited by the prospect of offering this patient population its potenti ...

The gross proceeds of the offering are $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness. Lowenstein Sandler, New York, NY, represented the Com ...

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. has successfully closed a public offering, raising gross proceeds of $4.0 million, which will be utilized for working capital, general corporate purposes, and preparation for a new drug application for its Tonmya™ product candidate targeting fibromyalgia [1][4]. Group 1: Offering Details - The public offering consisted of 1,199,448 shares of common stock priced at $1.065 per share and pre-funded warrants to purchase up to 2,568,110 shares at $1.064 each, with an exercise price of $0.001 per share [4]. - Dawson James Securities, Inc. acted as the sole placement agent for the offering [5]. - The offering was conducted under an effective shelf registration statement on Form S-3 previously filed with the SEC [6]. Group 2: Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders, with a priority to submit a New Drug Application for Tonmya in the second half of 2024 [13]. - The company has completed two statistically significant Phase 3 studies for Tonmya, which is intended for the management of fibromyalgia [13]. - Tonix's portfolio includes other product candidates targeting acute stress reaction, cocaine intoxication, organ transplant rejection, autoimmunity, and cancer [13].

The gross proceeds of the offering will be approximately $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness. This offering is being made pursuan ...